Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

BUY
$6.71 - $11.83 $142,325 - $250,926
21,211 New
21,211 $142,000
Q4 2021

Jan 21, 2022

SELL
$20.24 - $36.01 $103,223 - $183,651
-5,100 Closed
0 $0
Q3 2021

Nov 08, 2021

BUY
$26.01 - $38.22 $132,651 - $194,922
5,100 New
5,100 $163,000

Others Institutions Holding QURE

About uniQure N.V.


  • Ticker QURE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,729,100
  • Market Cap $270M
  • Description
  • uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...
More about QURE
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.